This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Evelo Biosciences, Inc.
4/29/2021
Good morning and welcome to Avello Biosciences conference call to discuss the first quarter 2021 financial results and business highlights. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open up the call for your questions. Please be advised that this call is being recorded at the company's request. At this time, I'd like to send the call over to Jessica Cotrone of Avello.
Please proceed. Thank you. This morning we issued a press release that outlines the topics we plan to discuss today. This release is available at www.avelobio.com under the Investors tab. Today on our call we have Simba Gill, Chief Executive Officer, Mark Bodmer, President of R&D and Chief Scientific Officer, and Jonathan Zung, Chief Development Officer. Before we begin, I would like to remind everyone that statements made during this conference call that do not relate to matters of historical fact including statements about our objectives and anticipated clinical milestones, the impact of our product candidates, and the timing and results of our clinical studies should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are intended to be subject to the safe harbor protection provided by the Reform Act. Actual results could differ materially from those indicated by the forward-looking statements due to the impact of many factors. Participants are directed to the risk factors set forth in Avello's quarterly report on Form 10-Q for the three months ended March 31, 2021, and the company's other filings with the Securities and Exchange Commission. Any forward-looking statements made today speak only to Avello's operations as of today. Avello disclaims any duty to provide updates to its forward-looking statements even if subsequent events cause the company's views to change. It is now my pleasure to pass the call over to Simba.
Thank you, Jessica. Good morning, everyone, and thanks for joining. 2021 is a pivotal year for us, and we've begun the year with continued strong execution. Together with our partners, we have successfully progressed our research and clinical plans despite the COVID-19 pandemic. And because of this, we remain on track to deliver multiple clinical readouts across psoriasis, atopic dermatitis, and COVID-19 over the next few months. We also continue to advance our extracellular vesicle product candidates in oncology and inflammatory disease. Mark's team in research and development continue to explore, enhance, and extend the applications of syntax-based medicines, and he will give you an overall view of our drug platform in a moment. We have expanded Avello's leadership, appointing Lucas Scarbo as chief financial officer. Lucas starts with us on June 1st. and Julie McHugh to a board of directors effective immediately. Both Luca and Julie have deep and successful track records in building global organizations and commercializing blockbuster products across a wide array of indications. We also announced a strategic collaboration with Abdul Latif Jamil Health to develop and commercialize EDP 1815 in the Middle East, Turkey, and Africa. The collaboration combines Abella's leadership in biotech innovation and Abdul Latif Jamil's regional presence, reputation, and expertise with the goal of accelerating the delivery of effective, affordable medicines to people in these high-growth markets. As we look forward, we continue to make strong progress in executing on our clinical strategy and plans, and Jonathan will tell you more about this later in the call. With that, I will pass the call over to Martin.
You're reading a preview of the EVLO Q1 2021 earnings call.
Free account.